Skip to main content

Advertisement

Table 2 Demographics. Child study

From: Arbaclofen in fragile X syndrome: results of phase 3 trials

Group/characteristic Placebo (N = 45) Arbaclofen Total (N = 169)
5 mg BID (N = 41) 10 mg BID (N = 41) 10 mg TID (N = 42)
Mean age (SD) 8.0 (2.20) 7.5 (1.86) 7.5 (1.81) 8.1 (2.02) 7.8 (1.99)
Gender (males) 38 (84.4%) 35 (83.3%) 35 (83.3%) 36 (83.7%) 144 (83.7%)
Race/ethnicity
 White non-hispanic 38 (84.4%) 29 (69.0%) 32 (76.2%) 36 (83.7%) 135 (78.5%)
 White hispanic 2 (4.4%) 2 (4.8%) 4 (9.5%) 3 (7.0%) 11 (6.4%)
 American Indian or Alaska Native 0 1 (2.4%) 0 0 1 (0.6%)
 African American 2 (4.4%) 2 (4.8%) 1 (2.4%) 1 (2.3%) 6 (3.5%)
 Asian 1 (2.2%) 3 (7.1%) 0 1 (2.3%) 5 (2.9%)
 Other 2 (4.4%) 5 (11.9%) 5 (11.9%) 2 (4.7%) 14 (8.1%)
Concomitant medications
 Any 33 (73.3%) 34 (81.0%) 28 (66.7%) 32 (74.4%) 127 (73.8%)
 Antipsychotics 12 (26.7%) 9 (21.4%) 4 (9.6%) 6 (14.0%) 31 (18.0%)
 None 12 (26.7%) 8 (19.0%) 14 (33.3%) 11 (25.6%) 45 (26.2%)
DSM-IV diagnosis of ASD 34 (75.6%) 32 (76.2%) 35 (83.3%) 35 (81.4%) 136 (79.1%)
Mean ABC-CFX Social Avoidance score (SD) 6.9 (3.49) 6.9 (2.84) 6.9 (3.03) 6.4 (2.92)  
  1. BID twice daily, TID three times daily, SD standard deviation, ASD autism spectrum disorder, ABC-C FX Aberrant Behavior Checklist refactored for FXS